5 Best ETF Charts Of Q4 Earnings

The Q4 earnings season has reached its tail end with 97.1% of the S&P 500 index market capitalization that has reported so far up 14% on 8.5% revenue growth, with 77.2% beating EPS estimates and 76% coming ahead of top-line expectations. Earnings and revenue growth rates are much higher for the same group of companies than in the past few quarters. Additionally, earnings and revenue surprises are also tracking above historical levels.

Investors should note that the gap between adjusted operating earnings and GAAP earnings is the widest in recent years due to huge one-time charges related to the new tax law.

Given this, several equity ETFs have impressed with their performances and generated handsome returns over the trailing one month even after being hit by the market rout triggered by inflation fears and higher-than-expected rates hike. While there are winners in many corners of the space, below are five ETFs that buoyed up on robust earnings results.

In addition, we have given a chart for their one-month performance and compared them with the broad market fund (AX:SPY) and the broad sector.

First Trust Nasdaq Semiconductor ETF FTXL

This fund offers exposure to the most-liquid U.S. semiconductor securities based on volatility, value and growth. Total earnings for the broad technology sector are up 23.4% on 10.8% higher revenues with a blended beat of 86.4%. Most of the growth comes from semiconductor companies, expected to post 68.8% earnings growth in Q4, representing an incredible surge from 33.8% earnings growth in the year-ago quarter. Given this, FTXL has gained 15.5% in the past month and boasts a Zacks ETF Rank #1 (Strong Buy) (read: 5 ETF Ways to Tap Hot Semiconductor Stocks).

Loncar Cancer Immunotherapy ETF CNCR

This product provides exposure to a basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system. The wave of mergers and acquisition talks as well as solid earnings from companies like Nektar Therapeutics (NASDAQ:NKTR) , Jounce Therapeutics (NASDAQ:JNCE) , Macrogenics (NASDAQ:MGNX) and Gilead Sciences (V:GLD) provided a boost to the fund’s portfolio. As a result, CNCR was up 13.3% over the past month and carries a Zacks ETF Rank #2 (Buy) with a High risk outlook (read: Biotech Crushing the Market: Best ETFs & Stocks YTD).

Guggenheim Solar ETF (LON:TAN)

This ETF offers exposure to the global companies involved in the solar power industry. It has gained 9.6% over the past month on strong Q4 earnings. In particular, earnings from First Solar (NASDAQ:FSLR) and SolarEdge Technologies (NASDAQ:SEDG) have been strong. These stocks occupy the top two positions and dominate the fund’s holdings with nearly double-digit exposure each (read: Alternative Energy ETFs to Gain From First Solar Q4 Results).




Amplify Online Retail ETF IBUY

This ETF offers global exposure to companies that derive 70% or more revenues from online and virtual retail. It has risen 8.8% in the past month. Both retail and e-commerce have reported robust Q4 results. Earnings and revenues for the retail sector are up 8.9% and 9.4%, respectively, while the beat ratios are lower than many other sectors. On the other hand, the Internet-ecommerce industry came up with a 50% earnings beat (read: 4 Market-Beating Sector ETFs & Stocks of February).

SPDR S&P Aerospace & Defense ETF (LON:XAR)

This product offers equal-weight exposure to the aerospace & defense sector of the broad U.S. market and gained 7.6% in a month. The robust performance was driven by strong Q4 earnings growth of 31.8% with a beat ratio of 81.8%, though revenue growth and revenue beat ratio is unimpressive at 7.3% and 45.5%, respectively. Additionally, the stock prices in response to earnings announcement for the sector have been the strongest of all with a 3.9% gain. XAR has a Zacks ETF Rank #1 with a Medium risk outlook (read: Can Aerospace & Defense ETFs Keep Soaring?).



Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>